MYC and cancer: In this context, a new series of 12 dibenzoquinoxaline derivatives was obtained, and, among them, compounds 13–15 (Scheme 5) were potent TopoI and c-MYC transcription inhibitors, also inhibiting cancer cell growth in TNBC cell lines, with IC50 values in the range of 1.0 μM (Table 3).